A Lochner1, S Genade, E Tromp, T Podzuweit, J A Moolman. 1. Department of Medical Physiology and Biochemistry, Faculty of Medicine, University of Stellenbosch, MRC Experimental Biology Programme, Tygerberg, Republic of South Africa. alo@gerga.sun.ac.za
Abstract
BACKGROUND: Previous studies from our laboratory showed cyclic increases in tissue cAMP during a multiple-cycle preconditioning (PC) protocol, followed by attenuated cAMP accumulation during sustained ischemia. The aim of this study was to determine whether ischemia-induced activation of the beta-adrenergic signaling pathway could act as a trigger in eliciting protection. METHODS AND RESULTS: Isolated perfused rat hearts were preconditioned by 3x5 minutes of global ischemia, interspersed by 5 minutes of reperfusion. beta-Adrenergic responsivity was assessed by measurement of tissue cAMP generation after beta-adrenergic agonist administration at the end of the PC protocol. Tissue cAMP, adenylyl cyclase, and protein kinase A (PKA) activities and beta-adrenergic receptor characteristics were assessed at different times. The role of cAMP generation in eliciting PC was studied by investigation of functional recovery during reperfusion after 25 minutes of global ischemia after (1) cAMP increases in the trigger period were prevented with the beta-adrenergic blocker alprenolol 7.5x10(-5) mol/L and (2) increases in cAMP were elicited by administration of forskolin 10(-7) and 10(-6) mol/L or isoproterenol 10(-8), 10(-7), and 10(-6) mol/L. Intermittent ischemia resulted in reduced beta-adrenergic responsivity at the end of the protocol, although B(max) and K(d) values of the beta-adrenergic receptor population and adenylyl cyclase and PKA activities were increased. Abolishment of cyclic increases in cAMP before sustained ischemia attenuated myocardial protection against ischemia, whereas agonists elicited protection. No clear correlation between protection and beta-adrenergic desensitization was observed. CONCLUSIONS: Ischemia-induced activation of the beta-adrenergic signaling pathway during preconditioning should also be considered a trigger in eliciting preconditioning.
BACKGROUND: Previous studies from our laboratory showed cyclic increases in tissue cAMP during a multiple-cycle preconditioning (PC) protocol, followed by attenuated cAMP accumulation during sustained ischemia. The aim of this study was to determine whether ischemia-induced activation of the beta-adrenergic signaling pathway could act as a trigger in eliciting protection. METHODS AND RESULTS: Isolated perfused rat hearts were preconditioned by 3x5 minutes of global ischemia, interspersed by 5 minutes of reperfusion. beta-Adrenergic responsivity was assessed by measurement of tissue cAMP generation after beta-adrenergic agonist administration at the end of the PC protocol. Tissue cAMP, adenylyl cyclase, and protein kinase A (PKA) activities and beta-adrenergic receptor characteristics were assessed at different times. The role of cAMP generation in eliciting PC was studied by investigation of functional recovery during reperfusion after 25 minutes of global ischemia after (1) cAMP increases in the trigger period were prevented with the beta-adrenergic blocker alprenolol 7.5x10(-5) mol/L and (2) increases in cAMP were elicited by administration of forskolin 10(-7) and 10(-6) mol/L or isoproterenol 10(-8), 10(-7), and 10(-6) mol/L. Intermittent ischemia resulted in reduced beta-adrenergic responsivity at the end of the protocol, although B(max) and K(d) values of the beta-adrenergic receptor population and adenylyl cyclase and PKA activities were increased. Abolishment of cyclic increases in cAMP before sustained ischemia attenuated myocardial protection against ischemia, whereas agonists elicited protection. No clear correlation between protection and beta-adrenergic desensitization was observed. CONCLUSIONS:Ischemia-induced activation of the beta-adrenergic signaling pathway during preconditioning should also be considered a trigger in eliciting preconditioning.
Authors: Sakthivel Sadayappan; Hanna Osinska; Raisa Klevitsky; John N Lorenz; Michelle Sargent; Jeffrey D Molkentin; Christine E Seidman; Jonathan G Seidman; Jeffrey Robbins Journal: Proc Natl Acad Sci U S A Date: 2006-10-30 Impact factor: 11.205
Authors: Peter E Penson; William R Ford; Emma J Kidd; Kenneth J Broadley Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-07-29 Impact factor: 3.000
Authors: Louise E See Hoe; Jan M Schilling; Anna R Busija; Kristofer J Haushalter; Victoria Ozberk; Malik M Keshwani; David M Roth; Eugene Du Toit; John P Headrick; Hemal H Patel; Jason N Peart Journal: Eur J Pharmacol Date: 2016-06-30 Impact factor: 4.432
Authors: Leslie C Thompson; Nicole L Sheehan; Dianne M Walters; Robert M Lust; Jared M Brown; Christopher J Wingard Journal: Cardiovasc Toxicol Date: 2019-04 Impact factor: 3.231
Authors: Amit Badhwar; Thomas L Forbes; Marge B Lovell; Alison A Dungey; Sarah D McCarter; Jeffrey R Scott; Guy DeRose; Kenneth A Harris; Richard F Potter Journal: Can J Surg Date: 2004-10 Impact factor: 2.089